• At J.P. Morgan, PacBio Updates on Impending Revio, Onso Shipments

    Bio-IT World | In his second J.P. Morgan Healthcare Conference address on behalf of Pacific Biosystems, CEO Christian Henry gave a summary of 2022 numbers and updates on the new sequencing platforms the company announced in October: the Revio long-read platform and the Onso short-read platform.

    Jan 13, 2023

  • Why Tech Transfer Needs a New Blueprint

    Bio-IT World | In BioPharma, development to manufacturing often feel as if they are separated by an invisible wall. While the enterprise may be joint, development and manufacturing cultures are distinct. Poor information sharing can make findings feel like closely guarded secrets. This siloed approach was the accepted norm in earlier eras. Now, it is due for a major renovation.

    Jan 13, 2023

  • At J.P. Morgan Illumina Reports Record-Breaking Uptake of NovaSeq X, Expanding Sequencing Market

    Bio-IT World | Illumina President and CEO Francis deSouza kicked off his annual J.P. Morgan Healthcare Conference presentation highlighting the breadth of the genomics market. deSouza sees a $120 billion total addressable market for Illumina, with oncology testing representing more than half of the opportunity.

    Jan 12, 2023

  • Three Pillars of 10x: Outlook for Single Cell, Spatial and In Situ Platforms

    Bio-IT World | Serge Saxonov, CEO and co-founder of 10x Genomics, kicked off Monday’s sessions at the 41st annual J.P. Morgan Healthcare Conference with an overview of the company’s overall progress in its Visium, Chromium, and Xenium platforms. Instead of delving too deeply in specific product announcements, Saxonov emphasized the strength of the 10x team, the mergers and acquisitions that have led to the development of the platforms, and the breadth of the company offerings.

    Jan 11, 2023

  • Genetic Engineering Breaks Ground In War Against Cancer

    Bio-IT World | Multiyear efforts using genetic engineering to study cancer development and interactions with components of the anti-tumor immune response were the subject of the Ernst W. Bertner Memorial Award keynote address delivered at the recent Leading Edge of Cancer Research Symposium of the University of Texas MD Anderson Cancer Center. The focus was on genetically engineered mouse models established to understand how cancer develops over time and to inform new approaches for both earlier detection and better treatment.

    Jan 10, 2023

  • Trendspotting: What’s Coming for Bio-IT in 2023

    Bio-IT World | We spoke with several leaders in the Bio-IT World community to gain insights about their predictions for the coming year. They anticipate increased use of AI and large language models for industry breakthroughs, significant data curation and computing advancements, widespread cost streamlining, and valiant efforts in pushing the boundaries of whole-genome studies.

    Jan 5, 2023

  • Mapping the Vagus Nerve: Researchers Look to Pave the Way for Bioelectronic Breakthroughs

    Bio-IT World | Researchers have their sights set on creating a first-of-its-kind anatomical map of the vagus nerve. The NIH-supported project plans to share the map with the greater scientific community in hopes of leading to new breakthroughs in the field of bioelectronic medicine.

    Jan 3, 2023

  • Top Stories of 2022: Sequencing, AI, and Creative Research

    Bio-IT World | Across the Bio-IT space this year, our top stories all focus on the new—new products, new sequencers, new chemistries, new research directions, and AI’s role in the future of precision medicine. It’s as if the industry as a whole is ready for something different.

    Dec 29, 2022

  • Vizgen’s Terry Lo on Creating Maps of Biology’s Backroads

    Bio-IT World | On the latest episode of the Trends from the Trenches podcast, Lo speaks with BioTeam’s Stan Gloss about spatial biology, why it matters, and how he imagines the technology changing healthcare’s future.

    Dec 27, 2022

  • Gene Editing in 3D Patient-Derived Tumor Organoids, Machine Learning Model As Diabetes Prevention Tool, More

    Bio-IT World | A novel mechanism for platelet activation in pathogenic blood clotting is also believed to limit inflammation during sepsis; supercomputing and AI resources apply large language models to track how a virus mutates into more dangerous or transmissible variants; Amazon Web Services to create, fund, and build 10 successful start-up companies based out of UNC-Chapel Hill; and more.

    Dec 27, 2022

  • Follow the Money: AI-Fueled Endoscopic Procedure Recording, New Computational Biological Center for Neurodegenerative Disease, More

    Bio-IT World | Funding for targeted cancer treatment AI platform, oligo-conjugated antibodies and nucleic acid-encoded pixels to identify and spatially locate cell surface proteins, life sciences SaaS solutions, and more.

    Dec 22, 2022

  • Killing Cancer With Synthetic Lethality

    Bio-IT World | A key member of the team that discovered the BRCA2 breast cancer susceptibility gene in 1995 is now enamored of the idea of taking on cancer with synthetic lethal therapies, a nontraditional approach that exploits the weaknesses of cancer cells. The promise of the treatment concept was the topic of the Heath Memorial Award keynote address delivered at the recent Leading Edge of Cancer Research Symposium of the University of Texas MD Anderson Cancer Center.

    Dec 21, 2022

  • Teachable Neurons Could Improve Preclinical Drug Screening

    Bio-IT World | When sent electrical signals, a living model of the brain succeeded in “playing” Pong, a simple, tennis-like computer game popular in the 1970s. It was a notable feat for a single layer of neural cells in a dish, recapitulating how a real brain functions better than a computer or artificial intelligence ever will.

    Dec 20, 2022

  • Why a Holistic Approach May Drastically Change the Way Experiments Are Conducted

    Bio-IT World | The rush to digitalization has been underway for some time, but there is one industry that remains stuck in the past: the life sciences. While there have been numerous advancements in the way drugs are developed, lab work continues to be dominated by out-of-date processes. Improving them isn’t going to move the dial. While they may help, they are not capable of producing the level of innovation that’s needed to take us to the next phase.

    Dec 16, 2022

  • Insilico Medicine’s AI-Driven Platform Pushes The Envelope Of Drug Discovery

    Bio-IT World | During a recent virtual unveiling party livestreamed from around the world, Insilico Medicine introduced the latest updates to Pharma.AI, its end-to-end drug discovery platform using generative artificial intelligence to discover new targets, design new molecules, and predict the outcome of clinical trials. Among the highlights were the addition of a knowledge graph to target discovery product PandaOmics and numerous new panels to generative chemistry engine Chemistry42.

    Dec 15, 2022

  • Insilico Medicine’s AI-Driven Platform Pushes The Envelope Of Drug Discovery

    Bio-IT World | During a recent virtual unveiling party livestreamed from around the world, Insilico Medicine introduced the latest updates to Pharma.AI, its end-to-end drug discovery platform using generative artificial intelligence to discover new targets, design new molecules, and predict the outcome of clinical trials. Among the highlights were the addition of a knowledge graph to target discovery product PandaOmics and numerous new panels to generative chemistry engine Chemistry42.

    Dec 15, 2022

  • In Virtual Trials, Two Alzheimer’s Drugs Do Poor Job Of Slowing Cognitive Decline

    Bio-IT World | Researchers from Duke, Penn State, and the University of Tennessee collaboratively built a mathematical model of Alzheimer’s disease that used real, de-identified patient data to simulate health outcomes from a pair of anti-amyloid-beta drugs. Notably, the virtual (aka in silico) clinical trials employed a computational approach that provides “individualized prescriptions” based on optimal timing and dosing of treatment while minimizing possible side effects.

    Dec 14, 2022

  • All of Us Announces First Return of Health-Related DNA Results

    Bio-IT World | The National Institutes of Health's All of Us Research Program has begun returning personalized health-related DNA results to more than 155,000 participants, with reports detailing whether participants have an increased risk for specific health conditions and how their body might process certain medications.

    Dec 13, 2022

  • Pregnancy Exposome A New Frontier In Personalized Medicine

    Bio-IT World | The importance of the pregnancy exposome on health was explored in depth by Barbara Cohn, Ph.D., director and senior research scientist at the Public Health Institute, at the Mayo Clinic’s recent Individualizing Medicine Conference. She has been an integral part of a groundbreaking, multigenerational study examining the ripple effects of chemical exposures on pregnant women and their offspring and the potential for metabolomics to drive individualized prevention and treatment.

    Dec 13, 2022

  • Deeper Mining Of Proteomics Data Using Artificial Intelligence

    Bio-IT World | Advances in mass spectrometry, ultra-high performance liquid chromatography, and bioinformatics have transformed proteomics research in recent years. The growing power of these technologies has contributed to the widespread application of bottom-up proteomics strategies, based on the characterization of proteins by analysis of peptides released through proteolytic digestion. However, challenges in proteomics data analysis remain, with traditional search strategies limiting the ability to fully interpret data.

    Dec 9, 2022